Weleader Biomedical Co (ROCO:7713) Beneish M-Score: -2.52 (As of Jul. 02, 2026)


ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
47 GF Score
Price NT$70.10
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Beneish M-Score?

Weleader Biomedical Co ROCO:7713 -1.54% 47 Beneish M-Score is -2.52 as of Jul. 02, 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 762 Medical Devices & Instruments companies, Weleader Biomedical Co ranks worse than 56.56% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.52 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Weleader Biomedical Co's Beneish M-Score or its related term are showing as below:

ROCO:7713' s Beneish M-Score Range Over the Past 10 Years
Min: -2.52   Med: -2.46   Max: -2.4
Current: -2.52

During the past 6 years, the highest Beneish M-Score of Weleader Biomedical Co was -2.40. The lowest was -2.52. And the median was -2.46.


Weleader Biomedical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Beneish M-Score Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 -2.40 -2.52

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 0.00 -2.81 -2.58 -2.52

ROCO:7713 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Weleader Biomedical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Weleader Biomedical Co Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Weleader Biomedical Co's Beneish M-Score falls into.


ROCO:7713
47GF Score
Weleader Biomedical Co Ltd ROCO:7713
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Weleader Biomedical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0408+0.528 * 0.9544+0.404 * 0.9863+0.892 * 1.1192+0.115 * 1.0336
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9609+4.679 * -0.042769-0.327 * 0.8924
=-2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$323 Mil.
Revenue was 295.19 + 295.891 + 273.086 + 245.133 = NT$1,109 Mil.
Gross Profit was 102.268 + 102.29 + 88.415 + 77.993 = NT$371 Mil.
Total Current Assets was NT$780 Mil.
Total Assets was NT$2,449 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,589 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$124 Mil.
Selling, General, & Admin. Expense(SGA) was NT$110 Mil.
Total Current Liabilities was NT$432 Mil.
Long-Term Debt & Capital Lease Obligation was NT$757 Mil.
Net Income was 57.739 + 59.827 + 50.011 + 40.978 = NT$209 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 133.117 + 47.484 + 60.715 + 71.979 = NT$313 Mil.
Total Receivables was NT$277 Mil.
Revenue was 247.911 + 255.54 + 252.622 + 235.052 = NT$991 Mil.
Gross Profit was 76.198 + 81.025 + 79.456 + 79.645 = NT$316 Mil.
Total Current Assets was NT$591 Mil.
Total Assets was NT$1,998 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,341 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$109 Mil.
Selling, General, & Admin. Expense(SGA) was NT$102 Mil.
Total Current Liabilities was NT$469 Mil.
Long-Term Debt & Capital Lease Obligation was NT$618 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(322.513 / 1109.3) / (276.871 / 991.125)
=0.290736 / 0.27935
=1.0408

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(316.324 / 991.125) / (370.966 / 1109.3)
=0.319157 / 0.334414
=0.9544

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (780.386 + 1588.84) / 2448.985) / (1 - (591.319 + 1340.769) / 1998.062)
=0.032568 / 0.033019
=0.9863

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1109.3 / 991.125
=1.1192

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(108.582 / (108.582 + 1340.769)) / (124.161 / (124.161 + 1588.84))
=0.074918 / 0.072482
=1.0336

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(109.84 / 1109.3) / (102.127 / 991.125)
=0.099017 / 0.103041
=0.9609

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((756.563 + 432.302) / 2448.985) / ((617.901 + 469.005) / 1998.062)
=0.485452 / 0.54398
=0.8924

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(208.555 - 0 - 313.295) / 2448.985
=-0.042769

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Weleader Biomedical Co has a M-score of -2.52 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.52 mean?
Weleader Biomedical Co (ROCO:7713) has a Beneish M-Score of -2.52 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Weleader Biomedical Co and its competitors. According to the industry distribution chart, Weleader Biomedical Co ranks #431 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 56.6%.
Is Weleader Biomedical Co's Beneish M-Score too high?
Weleader Biomedical Co's current Beneish M-Score is -2.52. Based on the distribution chart, Weleader Biomedical Co ranks #431 out of 762 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #431 out of 762 companies for Beneish M-Score. This places Weleader Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Beneish M-Score is -2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Beneish M-Score of -2.52. The current Beneish M-Score is -2.52. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Beneish M-Score is -2.52 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score

Get the complete analysis for ROCO:7713

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.10
Price